Longitudinal Assessment of Bile Duct Loss in Primary Biliary Cholangitis

INTRODUCTION: Bile duct involvement is a key finding of primary biliary cholangitis (PBC). The aim of this study was to evaluate baseline ductopenia and disease progression. METHODS: Retrospective longitudinal histological follow-up of treatment-naive patients with PBC. RESULTS: Eighty-three patients were included, with ductopenia correlated to fibrosis stage at baseline. The cumulative incidence of severe ductopenia remained stable after 5 years, whereas fibrosis continually increased over time. Baseline AST-to-Platelet Ratio Index and elevated alkaline phosphatase >2 times the normal with abnormal bilirubin were associated with ductopenia progression. DISCUSSION: Bile duct injury does not seem to follow the same course as fibrosis in PBC.

[1]  M. Manns,et al.  The challenges of primary biliary cholangitis: What is new and what needs to be done. , 2019, Journal of autoimmunity.

[2]  F. Nevens,et al.  Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response , 2019, Alimentary pharmacology & therapeutics.

[3]  G. Hirschfield,et al.  The Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review , 2019, Seminars in Liver Disease.

[4]  J. Boyer,et al.  Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[5]  A. Parés.  Primary biliary cholangitis. , 2018, Medicina clinica.

[6]  G. Hirschfield,et al.  EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. , 2017, Journal of hepatology.

[7]  Jiezhun Gu,et al.  Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements , 2017, Hepatology.

[8]  A. Burroughs,et al.  University of Birmingham Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy , 2022 .

[9]  A. Burroughs,et al.  Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. , 2014, Gastroenterology.

[10]  J. Neuberger,et al.  Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. , 2014, Journal of hepatology.

[11]  T. Arenovich,et al.  Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis , 2010, The American Journal of Gastroenterology.

[12]  C. Vincent,et al.  Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. , 2008, Gastroenterology.

[13]  F. Vleggaar,et al.  Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant , 2001, Gut.

[14]  B. Balkau,et al.  Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis , 1999 .

[15]  B. Balkau,et al.  Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. UDCA-PBC Group. , 1999, Journal of hepatology.

[16]  F. Colina,et al.  Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis. , 1992, Gastroenterology.

[17]  M. Navasa,et al.  Portal hypertension in primary biliary cirrhosis. Relationship with histological features. , 1987, Journal of hepatology.

[18]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .